Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 2, 2009, Pages 153-160

  Inoue, Tae ^a,b   Sugihara, Kazumi ^a   Ohshita, Hiroki ^b   Horie, Toru ^b   Kitamura, Shigeyuki ^c   Ohta, Shigeru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b PhoenixBio USA Corporation   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

7 hydroxywarfarin; Chimeric mice; CYP2C9; Human liver; S warfarin

Indexed keywords

ALBUMIN; CYTOCHROME P450 2C9; DRUG METABOLITE; TRITIUM; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; HEPATOCYTE TRANSPLANTATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PREDICTION; PRESCHOOL CHILD; RADIOACTIVITY; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION;

EID: 67649360011     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.153     Document Type: Article

References (40)

1. Lewis, R. J., Trager, W. F., Robinson, A. J. and Chan, K. K.: Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols. J. Lab. Clin. Med., 81: 925-931 (1973).
2. Shetty, H. G., Fennerty, A. G. and Routledge, P. A.: Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin. Pharmacokinet., 16: 238-253 (1989).
3. Takahashi, H. and Echizen, H.: Pharmacogenetics of warfarin elimination and its clinical implications. Clin. Pharmacokinet., 40: 587-603 (2001).
4. Kaminsky, L. S. and Zhang, Z.-Y.: Human P450 metabolism of warfarin. Pharmacol. Ther., 73: 67-74 (1997).
5. O'Reilly, R. A.: Studies on the optical enantiomorphs of warfarin in man. Clin. Pharmacol. Ther., 16: 348-354 (1794).
6. Chan, E., McLachlan, A. J., Pegg, M., MacKay, A. D., Cole, R. B. and Rowland, M.: Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br. J. Clin. Pharmacol., 37: 563-569 (1994).
7. Kaminsky, L. S., de Morais, S. M., Faletto, M. B., Dunbar, D. A. and Goldstein, J. A.: Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol. Pharmacol., 43: 234-239 (1993).
8. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawewnce, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J. and Trager, W. F.: Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 5: 54-59 (1992).
9. Rettie, A. E., Eddy, A. C., Heimark, L. D., Gibaldi, M. and Trager, W. F.: Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos., 17: 265-270 (1989).
10. Yamazaki, H. and Shimada, T.: Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem. Pharmacol., 54: 1195-1203 (1997).
11. Black, D. J., Kunze, K. L., Wienkers, L. C., Gidal, B. E., Seaton, T. L., McDonnell, N. D., Evans, J. S., Bauwens, J. E. and Trager, W. F.: Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos., 24: 422-428 (1996).
12. Kunze, K. L., Wienkers, L. C., Thummel, K. E., Trager, W. F. and Warfarin-fluconazole. I.: Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos., 24: 414-421 (1996).
13. Kunze, K. L. and Trager, W. F.: Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Drug Metab. Dispos., 24: 429-435 (1996).
14. Lewis, R. J., Trager, W. F., Chan, K. K., Breckenridge, A., Orme, M., Roland, M. and Schary, W.: Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J. Clin. Invest., 53: 1607-1617 (1974).
15. Scordo, M. G., Pengo, V., Spina, E., Dahl, M. L., Gusella, M. and Padrini, R.: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther., 72: 702-710 (2002).
16. Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T., Kimura, S. and Echizen, H.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther., 73: 253-263 (2003).
17. Vesell, E. S. and Shively, C. A.: Liquid chromatographic assay of warfarin: similarity of warfarin half-lives in human subjects. Science, 26: 466-468 (1974).
18. Greenblatt, D. J. and von Moltka, L. L.: Interaction of warfarin with drugs, natural substances and foods. J. Clin. Pharmacol., 45: 127-132 (2005).
19. Takahashi, H., Kashima, T., Kimura, S., Murata, N., Takaba, T., Iwade, K., Abe, T., Tainaka, H., Yasumori, T. and Echizen, H.: Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of in vitro approaches to predicting in vivo reduction of (S)-warfarin clearance. Drug Metab. Dispos., 27: 1179-1186 (1999).
20. Cropp, J. S. and Bussey, H. I.: A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacother., 17: 917-928 (1997).
21. Nishimura, M., Yokoi, T., Tateno, C., Kataoka, M., Takahashi, E., Horie, T., Yoshizato, K. and Naito, S.: Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab. Pharmacokinet., 20: 121-126 (2005).
22. Katoh, M., Matsui, T., Nakajima, M., Tateno, C., Kataoka, M., Soeno, Y., Horie, T., Iwasaki, K., Yoshizato, K. and Yokoi, T.: Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab. Dispos., 32: 1402-1410 (2004).
23. Katoh, M., Matsui, T., Okumura, H., Nakajima, M., Nishimura, M., Naito, S., Tateno, C., Yoshizato, K. and Yokoi, T.: Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab. Dispos., 33: 1333-1340 (2005).
24. Katoh, M., Tateno, C., Yoshizato, K. and Yokoi, T.: Chimeric mice with humanized liver. Toxicology, 246: 9-17 (2008).
25. Katoh, M., Matsui, T., Sawada, T., Soeno, Y., Nakajima, M., Tateno, C., Yoshizato, K. and Yokoi, T.: In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J. Pharm. Sci., 96: 428-437 (2006).
26. Katoh, M., Matsui, T., Nakajima, M., Tateno, C., Soeno, Y., Horie, T., Iwasaki, K., Yoshizato, K. and Yokoi, T.: In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab. Dispos., 33: 754-763 (2005).
27. Okumura, H., Katoh, M.,Wawada, T., Nakajima, M., Soeno, Y., Yabuuchi, H., Ikeda, T., Tateno, C., Yoshizato, K. and Yokoi, T.: Humanization of excretory pathway in chimeric mice with humanized liver. J. Toxicol. Sci., 97: 533-538 (2007).
28. Kitamura, S., Nitta, K., Tayama, Y., Tanoue, C., Sugihara, K., Inoue, T., Horie, T. and Ohta, S.: Aldehyde oxidase-catalyzed metabolism of N1-methylnicotinamide in vivo and in vitro in chimeric mice with humanized liver. Drug Metab. Dispos., 36: 1202-1205.
29. Tateno, C., Yoshizane, Y., Saito, N., Kataoka, M., Utoh, R., Yamasaki, C., Tachibana, A., Soeno, Y., Asahina, K., Hino, H., Asahara, T., Yokoi, T., Furukawa, T. and Yoshizato, K.: Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol., 165: 901-912 (2004).
30. Takahashi, H., Kashima, T., Kimura, S.,Muramoto, N., Nakahata, H., Kubo, S., Shimoyama, Y., Kajiwara, M. and Echizen, H.: Determination of unbound warfarin enantiomers in human plasma and 7-hydroxywarfarin in human urine by chiral stationary-phase liquid chromatography with ultraviolet or fluorescence and on-line. J. Chromatogr. B, 7: 71-80 (1997).
31. Lang, D. and Bocker, R.: Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J. Chromatogr. B, 672: 305-309 (1995).
32. Doumas, B. T., Watson, W. A. and Biggs, H. G.: Albumin standards and the measurement of serum albumin with bromcresol green. Clin. Chim. Acta, 31: 87-96 (1971).
33. Andreasen, P. B. and Vesell, E. S.: Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration. Clin. Pharmacol. Ther., 16: 1059-1065 (1974).
34. O'Reilly, R. A., Aggeler, P. M. and Leong, L. S.: Studies on the coumarin anticoagulant drugs: a comparison of the pharmacodynamics of dicoumarol and warfarin in man. Thromb. Diath. Haemorrh., 15: 1-22 (1964).
35. Heimark, L. D., Gibaldi, M., Trager, W. F., O'Reilly, R. A. and Goulart, D. A.: The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther., 42: 388-394 (1987).
36. Banfield, C., O'Reilly, R., Chan, E. and Rowland, M.: Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br. J. Clin. Pharmacol., 16: 669-675 (1983).
37. Fasco, M. J. and Cashin, M. J.: Effects of induction on R- and S-warfarin and metabolite concentrations in rat plasma. Toxicol. Appl. Pharmacol., 56: 101-109 (1980).
38. Griffin, S. J. and Houston, J. B.: Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance., 32: 552-558 (2004).
39. Obaseki, A. O., Jayaraj, A. and Porter, W. R.: Effect of thioacetamide-induced hepatic necrosis on the regioselective metabolism of S-warfarin by rat liver mixed-function oxidase enzymes. Biochem. Pharmacol., 32: 2385-2391 (1983).
40. Zhou, Q. and Chan, E.: Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur. J. Pharm. Sci., 20: 439-449 (2003).